-
EP2729176
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2729176
| EP2729176 - THE USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 20.02.2015 Database last updated on 15.06.2024 | Most recent event Tooltip | 20.02.2015 | Application deemed to be withdrawn | published on 25.03.2015 [2015/13] | Applicant(s) | For all designated states Contera Pharma ApS Kvæsthusgade 5C, 4. 1251 København K / DK | [N/P] |
| Former [2014/20] | For all designated states Contera Pharma APS Kvæsthusgade 5C, 4. 1251 København K / DK | Inventor(s) | 01 /
HANSEN, John Bondo Langåsen 3 DK-4450 Jyderup / DK | 02 /
THOMSEN, Mikael S. Hvidovre Allé 18 DK-2650 Hvidovre / DK | [2014/20] | Representative(s) | Høiberg P/S Adelgade 12 1304 Copenhagen K / DK | [N/P] |
| Former [2014/20] | Høiberg A/S St. Kongensgade 59 A 1264 Copenhagen K / DK | Application number, filing date | 12740883.9 | 05.07.2012 | WO2012DK50254 | Priority number, date | US201161504371P | 05.07.2011 Original published format: US 201161504371 P | [2014/20] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013004249 | Date: | 10.01.2013 | Language: | EN | [2013/02] | Type: | A1 Application with search report | No.: | EP2729176 | Date: | 14.05.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.01.2013 takes the place of the publication of the European patent application. | [2014/20] | Search report(s) | International search report - published on: | EP | 10.01.2013 | Classification | IPC: | A61K47/00, A61P25/14 | [2014/20] | CPC: |
A61K45/06 (EP,US);
A61K31/506 (US);
A61K31/216 (US);
A61K31/27 (EP,US);
A61K31/44 (US);
A61K31/505 (EP,US);
A61P25/14 (EP)
(-)
| C-Set: |
A61K31/27, A61K2300/00 (EP);
A61K31/505, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/20] | Title | German: | VERWENDUNG VON SEROTONIN-REZEPTORAGONISTEN ZUR BEHANDLUNG VON BEWEGUNGSSTÖRUNGEN | [2014/20] | English: | THE USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS | [2014/20] | French: | UTILISATION D'AGONISTES DE RÉCEPTEUR DE SÉROTONINE POUR LE TRAITEMENT DE TROUBLES DES MOUVEMENTS | [2014/20] | Entry into regional phase | 05.02.2014 | National basic fee paid | 05.02.2014 | Designation fee(s) paid | 05.02.2014 | Examination fee paid | Examination procedure | 05.02.2014 | Examination requested [2014/20] | 25.09.2014 | Application deemed to be withdrawn, date of legal effect [2015/13] | 25.09.2014 | Loss of particular rights, legal effect: Claims | 04.11.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time [2015/13] | 04.11.2014 | Despatch of communication of loss of particular rights: Claims {1} | Fees paid | Penalty fee | Additional fee for renewal fee | 31.07.2014 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A] - BARA-JIMENEZ ET AL, "Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.", MOVEMENT DISORDERS, (2005), vol. 20, no. 8, pages 932 - 936, XP002682390 [A] 1-46 * abstract * DOI: http://dx.doi.org/10.1002/MDS.20370 | [A] - GOETZ ET AL, "Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.", MOVEMENT DISORDERS, (2007), vol. 22, no. 2, pages 179 - 186, XP002682391 [A] 1-46 * abstract * DOI: http://dx.doi.org/10.1002/mds.21226 | [A] - RICHTER A; SANDER S E; RUNDFELDT C, "Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia.", BR.J.PHARMACOLOGY, (2006), vol. 149, pages 747 - 753, XP002682392 [A] 1-46 * abstract * DOI: http://dx.doi.org/10.1038/SJ.BJP.0706878 | by applicant | US5431922 | US5633009 | WO0166081 | WO02080898 | EP1266656 | WO2006092143 | US2007191351 | WO2008066900 | EP2206699 | EP2206700 | WO2011026890 | - JENNER, NAT REV NEUROSCI., (2008), vol. 9, no. 9, pages 665 - 77 | - DEL SORBO; ALBANESE, J NEUROL., (2008), vol. 255, no. 4, pages 32 - 41 | - FILIP ET AL., PHARMACOL. REPORTS, (2009), vol. 61, pages 761 - 777 | - OHNO, CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY, (2010), vol. 10, pages 148 - 157 | - NEWMAN-TANCREDI, CURRENT OPINION IN INVESTIGATIONAL DRUGS, (2010), vol. 11, no. 7, pages 802 - 812 | - MOSS ET AL., J CLIN PSYCHOPHARMACOL., (1993), vol. 13, pages 204 - 9 | - JENTSCH, NATURE REVIEWS NEUROSCIENCE, (2000), vol. 1, pages 21 - 30 | - WULFF, NAT REV DRUG DISCOV., (200912), vol. 8, no. 12, pages 982 - 1001 | - XIONG ET AL., TRENDS PHARMACOL SCI., (200802), vol. 29, no. 2, pages 99 - 107 | - BERGE S.M. ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, pages 1 - 19 | - J. PHARM. SCI., (1977), vol. 66, page 2 | - T. HIGUCHI; V STELLA, Pro-drugs as Novel Delivery Systems, A.C.S. SYMPOSIUM SERIES, vol. 14 | - BONIFATI ET AL., CLIN NEURPHARMACOL, (1994), vol. 17, pages 73 - 82 | - DEKUNDY ET AL., BEHAVIOURAL BRAIN RESEARCH, (2007), vol. 179, pages 76 - 89 | - ELANGBAM ET AL., J HISTOCHEM CYTOCHEM, (2005), vol. 53, pages 671 - 677 | - FOX ET AL., MOVEMENT DISORDERS, (2009), vol. 24, no. 9 | - GREGOIRE ET AL., PARKINSONISM RELAT DISORD., (2009), vol. 15, no. 6, pages 445 - 52 | - KIRIK ET AL., J. NEUROSCI, (2001), vol. 21, pages 2889 - 96 | - MOSS ET AL., J CLIN PSYCHOPHARMACOL., (199306), vol. 13, no. 3, pages 204 - 9 | - MUNOZ ET AL., BRAIN, (2008), vol. 131, pages 3380 - 94 | - MUNOZ ET AL., EXPERIMENTAL NEUROLOGY, (2009), vol. 219, pages 298 - 307 | - ROPPONGI ET AL., PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, (2007), vol. 31, no. 1, pages 308 - 10 | - SCHALLERT ET AL., J. NEURAL TRANSPL PLAST, (1992), vol. 3, pages 332 - 3 | - WULFF ET AL., NAT REV DRUG DISCOV., (200912), vol. 8, no. 12, pages 982 - 1001 | - XIONG Q; GAO Z; WANG W; LI M., TRENDS PHARMACOL SCI, (200802), vol. 29, no. 2, pages 99 - 107 | - BLOM ET AL., PLOS ONE, (2009), vol. 4, page E8251 |